Welcome to our dedicated page for Ascentage Pharma Group International news (Ticker: AAPG), a resource for investors and traders seeking the latest updates and insights on Ascentage Pharma Group International stock.
Ascentage Pharma Group International reports recurring developments in cancer-focused drug commercialization and clinical development. The company is a global, commercial-stage integrated biopharmaceutical issuer with American depositary shares on Nasdaq and ordinary shares listed on HKEX. Its updates center on Olverembatinib, a third-generation BCR-ABL inhibitor approved in China, and Lisaftoclax, a China-developed Bcl-2 selective inhibitor, as well as oncology candidates such as Alrizomadlin, APG-2449, APG-5918 and APG-3288.
News from AAPG also covers clinical and preclinical data presented at oncology meetings, regulatory clearances for investigational studies, full-year financial results, commercial activity in China, pipeline progress in hematologic malignancies and solid tumors, and investor-conference communications.
Ascentage Pharma (NASDAQ:AAPG; HKEX:6855) will present 17 clinical advances at the 31st European Hematology Association (EHA2026) Congress in Stockholm from June 11–14, 2026, including 8 posters.
Data cover ongoing studies of Olverembatinib (HQP1351) and Lisaftoclax (APG-2575), both approved in China but not yet FDA-approved in the US.
Ascentage Pharma (NASDAQ:AAPG), a global commercial-stage biopharma company focused on oncology, will participate in three upcoming investor conferences in May and June 2026.
Management will hold one-on-one meetings, a fireside chat, and a presentation, with webcasts available via the company’s Investor Relations Events page.
Ascentage Pharma (NASDAQ: AAPG) will present six clinical abstracts at the ASCO 2026 Annual Meeting (May 29–June 2, 2026), including three rapid oral presentations and three poster presentations across hematologic and pediatric oncology.
Highlights include data on olverembatinib (HQP1351), lisaftoclax (APG-2575) and alrizomadlin (APG-115), ongoing phase 3 registrational trials (POLARIS-2, GLORA), and presentations covering leukemia, sarcoma, CLL/SLL, and pediatric relapsed/metastatic sarcomas.
Ascentage Pharma (NASDAQ: AAPG) will present four preclinical posters at AACR 2026 (April 17–22, 2026) highlighting combination strategies for Olverembatinib (HQP1351), APG-2449 and APG-5918. Key takeaways: Olverembatinib shows synergy with chemotherapy and BTK inhibition; APG-2449 enhances BRAF-targeted therapy; APG-5918 primes SCLC for topoisomerase I inhibitors.
These findings aim to inform clinical development and complement ongoing registrational trials while addressing resistance mechanisms across hematologic and solid tumors.
Ascentage Pharma (NASDAQ: AAPG) reported unaudited 2025 results: revenue US$82.1M (-41.5% YoY) and a loss of US$177.7M. Product sales rose as Olverembatinib reached US$62.2M (+80.6%) and Lisaftoclax generated US$10.1M after its July launch.
R&D was US$162.7M (+20.1%), selling/distribution US$50.6M (+80.4%), and cash was US$353.2M following 2025 equity offerings. Nine registrational Phase III trials are underway, several cleared by FDA and EMA.
Ascentage Pharma (NASDAQ: AAPG) will present four preclinical posters at the AACR Annual Meeting 2026 in San Diego, April 17–22, 2026. The abstracts cover olverembatinib (HQP1351), APG-2449, and APG-5918, reporting efficacy and synergies in multiple tumor models.
The posters detail combination activity with chemotherapy, BTK inhibition, MAPK blockade, and topoisomerase I inhibitors in endometrial, mantle cell, BRAF V600E-mutant, and small-cell lung cancer preclinical models. None of the three candidates are FDA approved.
Ascentage Pharma (NASDAQ: AAPG) will release its full year 2025 unaudited financial results and provide business updates on March 25, 2026 (7:00 pm EDT) / March 26, 2026 (HKT). The company will host investor webcasts in English and Chinese with live Q&A and a replay available for the English presentation.
Analysts and investors must register in advance to access the respective language webcasts; timings: Chinese webcast at 10:00 pm EDT on March 25, 2026, and English webcast at 8:00 am EDT on March 26, 2026.
Ascentage Pharma (NASDAQ: AAPG) said management will participate in three investor conferences: Oppenheimer (Feb 25 presentation), TD Cowen (Mar 4 fireside chat) and Jefferies Biotech on the Beach (Mar 10–11 meetings).
Webcasts for the presentation and fireside chat will be available via the Events page in the company's Investor Relations website.
Ascentage Pharma (NASDAQ: AAPG) announced management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026. The team will appear in a fireside chat at 9:30 am ET on Thursday, February 12, 2026.
The live webcast can be accessed via the Events page in the company's Investor Relations website.
Ascentage Pharma (NASDAQ: AAPG) announced that its next‑generation BTK degrader APG-3288 received IND clearance from the China Center for Drug Evaluation on Feb 5, 2026, following earlier U.S. FDA IND clearance.
The company will start a multicenter, open‑label Phase I study in relapsed/refractory hematologic malignancies to evaluate safety, tolerability, PK, and preliminary efficacy.